[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344693-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344693-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-impact-of-inhibiting-the-hippo-signaling-pathway-effector-molecule-yap1-on-in-vitro-glioblastoma-and-glioblastoma-stem-cells","The impact of inhibiting the Hippo signaling pathway effector molecule YAP1 on in vitro glioblastoma and glioblastoma stem cells","","Study evaluates Hippo pathway effector YAP1 as a therapeutic target in glioblastoma by combining siRNA-mediated YAP1 silencing with testing of the new inhibitor CA3 (CIL56). Experiments compared glioblastoma and glioblastoma stem cells with healthy brain stem cells and human brain microvascular endothelial cells. Anti-tumoral effects were measured via Annexin V-FITC apoptosis assay, ferroptosis assessment using GPX activity, and cell-cycle analysis, alongside invasion, migration, EMT marker evaluation, spheroid stemness assays, and qRT-PCR gene-expression profiling.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-impact-of-inhibiting-the-hippo-signaling-pathway-effector-molecule-yap1-on-in-vitro-glioblastoma-and-glioblastoma-stem-cells/344693/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-impact-of-inhibiting-the-hippo-signaling-pathway-effector-molecule-yap1-on-in-vitro-glioblastoma-and-glioblastoma-stem-cells/344693.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapeutic strategy does the study test for glioblastoma?","Question",{"text":63,"@type":64},"The study evaluates YAP1 inhibition using siRNA-mediated silencing and the new small-molecule inhibitor CA3 (CIL56). It aims to suppress glioblastoma growth and related cellular behaviors in vitro.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are anti-tumor effects assessed in glioblastoma cells and stem cells?",{"text":68,"@type":64},"Cell death and downstream outcomes are measured with Annexin V-FITC assays, ferroptosis assessment via GPX activity, and cell-cycle analysis. Invasion and migration assays, EMT marker evaluation, and spheroid formation are also used to characterize motility and stemness changes.",{"name":70,"@type":61,"acceptedAnswer":71},"What do the findings suggest about CA3 (CIL56)?",{"text":72,"@type":64},"The results indicate that both YAP1 silencing and CA3 (CIL56) inhibition produce significant anti-tumoral effects on glioblastoma cell viability, motility, and stemness, with CA3 showing notable impact on stem cells, supporting further investigation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344693,1790637346,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nThe impact of inhibiting the Hippo signaling pathway effector molecule YAP1 on in vitro glioblastoma and glioblastoma stem cells  \nNeslihan Pinar Ozates1,6􀀍, Bakiye Goker Bagca2, AycanAsik3, Cumhur Gunduz4, Haluk Akin5 & Cigir Biray Avci4  \nGlioblastoma, a prevalent and aggressive brain tumor in adults, recurs due to local invasiveness, radiation therapy failure, drug resistance, and cancer stem cell presence. The Hippo signaling pathway, regulating organ size and growth, features YAP as a key effector with oncogenic implications in various cancers, including glioma. This study aimed to explore YAP1 as a therapeutic target in glioblastoma by silencing it using siRNA and evaluating the potential of a new inhibitor, CA3 (CIL56), through advanced in vitro analyses. Investigations were conducted on brain cancer and stem cells, alongside healthy brain stem cells and human brain microvascular endothelial cells. Effects of CA3 (CIL56) andYAP1 siRNA on cell lines were gauged through Annexin V-FITC assay, ferroptosis assay (GPX activity), and cell cycle analysis. Invasion and migration assays, along with epithelial-mesenchymal transition marker evaluations, assessed cell movement effects. Spheroid formation examined stemness effects, with qRT-PCR measuring gene expression changes. Findings indicate that siRNA-mediated YAP1 silencing and CA3 (CIL56) inhibition exert significant, though varying, anti-tumoral effects on glioblastoma cell viability, motility, and stemness. Notably, CA3’s impact on stem cells highlights its potential as a promising therapeutic target, meriting further investigation.  \nKeywords Glioblastoma, YAP1, SiRNA, CA3, Ferroptosis  \nAbbreviations  \nACC1 Acetyl-CoA carboxylase 1  \nAPC adenomatosis polyposis coli tumor suppressor BCSC Brain cancer stem cell  \nBSC Brain stem cell  \nCA3 CIL56; 2,7-bis(1-piperidinylsulfonyl)-9 H-fluoren-9-one, oxime Ccd42 Cell division cycle 42  \nCTGF Connective tissue growth factor  \nCTNNB Catenin Beta  \nCYR61 Cysteine-rich angiogenic inducer 61 EMT Epithelial-mesenchymal transition  \nFAK Focal adhesion kinase  \nGBM Glioblastoma  \nHBMEC Human brain microvascular endothelial cell IQGAP1 IQ Motif Containing gtpase Activating Protein 1 LATS Large tumor suppressor kinases  \n1Department of Medical Biology, Faculty of Medicine, Harran University, Sanliurfa, Turkey. 2Department of Medical Biology, Faculty of Medicine, Ege University, İzmir, Turkey. 3Department of Medical Biology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey. 4Department of Medical Biology, Faculty of Medicine, Ege University,İzmir, Turkey. 5Department of Medical Genetics, Faculty of Medicine, Ege University, İzmir, Turkey. 6Medical Faculty, Department of Medical Biology, Ege University, İzmir, Turkey. 􀀍 email: [neslihan.ozates@harran.edu.tr](neslihan.ozates@harran.edu.tr); [npozates@gmail.com](npozates@gmail.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nmTOR Mechanistic target of rapamycin kinase  \nNF2 Moesin-ezrin-radixin like (merlin) tumor suppressor qRT-PCR Quantitative real time polymerase change reaction siRNA Small interfering RNA  \nT98G GBM cell line  \nTAZ Tafazzin, phospholipid-lysophospholipid transacylase TEAD TEA domain family member  \nTWIST Twist family BHLH transcription factor WNT Wingless-type MMTV ıntegration site family YAP Yes-associated protein  \nGlioblastoma (GBM), originating from glial cells, is the most common and lethal brain cancer1. Despite standard treatments, including surgery, radiotherapy, and temozolomide-based therapies over 12–15 months, only 3–5% of patients survive beyond five years2. Challenges like GBM’s molecular heterogeneity and the bloodbrain barrier limit therapeutic effectiveness, resulting in recurrence. Recurrence is driven by local invasiveness, radiotherapy resistance, drug inefficacy, and cancer stem cell populations, with no curative surgical op","cbCaivngkt7TYKXL","https://ap.wps.com/l/cbCaivngkt7TYKXL","pdf",19183696,25,"English","# Introduction\n## Glioblastoma background and treatment challenges\n## Rationale for targeting the Hippo pathway\n# Prior evidence for YAP1 in brain tumors\n## Expression patterns and neural stem cell links\n# Study approach for YAP1 inhibition\n## CA3 (CIL56) and YAP1 siRNA experimental design","[{\"question\":\"What therapeutic strategy does the study test for glioblastoma?\",\"answer\":\"The study evaluates YAP1 inhibition using siRNA-mediated silencing and the new small-molecule inhibitor CA3 (CIL56). It aims to suppress glioblastoma growth and related cellular behaviors in vitro.\"},{\"question\":\"How are anti-tumor effects assessed in glioblastoma cells and stem cells?\",\"answer\":\"Cell death and downstream outcomes are measured with Annexin V-FITC assays, ferroptosis assessment via GPX activity, and cell-cycle analysis. Invasion and migration assays, EMT marker evaluation, and spheroid formation are also used to characterize motility and stemness changes.\"},{\"question\":\"What do the findings suggest about CA3 (CIL56)?\",\"answer\":\"The results indicate that both YAP1 silencing and CA3 (CIL56) inhibition produce significant anti-tumoral effects on glioblastoma cell viability, motility, and stemness, with CA3 showing notable impact on stem cells, supporting further investigation.\"}]","The impact of inhibiting the Hippo signaling pathway effector molecule YAP1 on in vitro glioblastoma and glioblastoma stem cells | PDF",1790054951,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24fe1c27c26521fa23191c38751fc825.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7605d0e19597e47c8626b72afe18919.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41d465cdde77040e0ec03234f88221d7.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f08b17e7892523241c9527998d35e34e.webp",980,1287]